The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines
暂无分享,去创建一个
Seiichi Hirota | Yoon-Koo Kang | Jean-Yves Blay | S. Hirota | J. Blay | Yoon-Koo Kang | T. Nishida | Toshirou Nishida | Yuko Kitagawa | Y. Kitagawa
[1] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[2] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[3] J. Desai,et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] T. Nakajima,et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. , 2006, Human pathology.
[5] Heikki Joensuu,et al. Gastrointestinal stromal tumour , 2013, The Lancet.
[6] J. Blay,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[7] L. Terracciano,et al. Microscopic Gastrointestinal Stromal Tumors in Esophageal and Intestinal Surgical Resection Specimens: A Clinicopathologic, Immunohistochemical, and Molecular Study of 19 Lesions , 2008, The American journal of surgical pathology.
[8] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[9] J. Crowley,et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[11] M. Heinrich,et al. Gastrointestinal stromal tumour , 2007, The Lancet.
[12] Aki Vehtari,et al. Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients. , 2014, Radiology.
[13] J. Manola,et al. Cytoreductive Surgery in Patients with Metastatic Gastrointestinal Stromal Tumor Treated with Sunitinib Malate , 2010, Annals of Surgical Oncology.
[14] J. Manola,et al. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. , 2014, European journal of cancer.
[15] P. Casali,et al. Gastrointestinal stromal tumours : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow-up , 2010 .
[16] Eun Hye Kim,et al. Impact of Periodic Endoscopy on Incidentally Diagnosed Gastric Gastrointestinal Stromal Tumors: Findings in Surgically Resected and Confirmed Lesions , 2015, Annals of Surgical Oncology.
[17] Aki Vehtari,et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.
[18] Aki Vehtari,et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. , 2012, The Lancet. Oncology.
[19] G. Demetri,et al. Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132 , 2012, Annals of Surgical Oncology.
[20] Ke Chen,et al. Systematic review and meta-analysis of safety and efficacy of laparoscopic resection for gastrointestinal stromal tumors of the stomach , 2015, Surgical Endoscopy.
[21] A. D. Van den Abbeele,et al. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. , 2005, Radiology.
[22] J. Blay,et al. Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era , 2012, Clinical Cancer Research.
[23] J. Blay,et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] C. Antonescu,et al. Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor , 2007, Annals of surgery.
[25] K. S. Hall,et al. Gastrointestinal Stromal Tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 25, pg iii21, 2014) , 2015 .
[26] J. Blay,et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] J. Blay,et al. Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. , 2015, The oncologist.
[28] T. Nishida,et al. Submucosal tumors: Comprehensive guide for the diagnosis and therapy of gastrointestinal submucosal tumors , 2013, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.
[29] T. Hwang,et al. Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan , 2012, World Journal of Surgical Oncology.
[30] P. Vilmann,et al. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline , 2011, Endoscopy.
[31] J. Blay,et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. , 2005, European journal of cancer.
[32] J. Sicklick,et al. Epidemiology of Gastrointestinal Stromal Tumors in the Era of Histology Codes: Results of a Population-Based Study , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[33] C. Antonescu,et al. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. , 2012, Journal of the American College of Surgeons.
[34] K. Owzar,et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts) , 2007 .
[35] M. van Glabbeke,et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. , 2004, European journal of cancer.
[36] J. Jónasson,et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Blay,et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Fletcher,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] K. Owzar,et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] P. Rutkowski,et al. Succinate Dehydrogenase-Deficient GISTs: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 66 Gastric GISTs With Predilection to Young Age , 2011, The American journal of surgical pathology.
[42] C. Antonescu,et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] C. Antonescu,et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[44] S. Hirota,et al. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy , 2007, International Journal of Clinical Oncology.
[45] G. Demetri,et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. , 2013, The Lancet. Oncology.
[46] J. Fletcher,et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] J. Lasota,et al. Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.
[48] L. Sobin,et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.
[49] B. Nilsson,et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.
[50] G. Demetri,et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] M. Heinrich,et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. , 2002, The American journal of pathology.
[52] S. Hirota,et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene , 1998, Nature Genetics.
[53] H. Joensuu,et al. Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. , 2015, European journal of cancer.
[54] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[55] C. Antonescu,et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. , 2009, The Lancet. Oncology.
[56] S. Hirota,et al. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version , 2008, International Journal of Clinical Oncology.
[57] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] C. Antonescu,et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.